Zacks Research Issues Positive Outlook for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Investment analysts at Zacks Research lifted their Q4 2026 earnings per share estimates for Pacira BioSciences in a research note issued to investors on Tuesday, February 11th. Zacks Research analyst R. Department now anticipates that the company will earn $0.83 per share for the quarter, up from their previous forecast of $0.79. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.40 per share.

Other analysts have also issued reports about the stock. HC Wainwright restated a "buy" rating and set a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and increased their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada restated a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Barclays dropped their price objective on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research note on Tuesday, November 12th. Finally, Needham & Company LLC increased their price objective on Pacira BioSciences from $22.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $22.78.

Pacira BioSciences Trading Down 4.1 %

Shares of Pacira BioSciences stock traded down $1.09 during trading on Thursday, reaching $25.44. The company's stock had a trading volume of 615,935 shares, compared to its average volume of 924,745. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $31.67. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -12.53 and a beta of 0.80. The firm's 50-day moving average is $22.00 and its two-hundred day moving average is $18.13. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Institutional Investors Weigh In On Pacira BioSciences

Several institutional investors and hedge funds have recently modified their holdings of PCRX. Nuveen Asset Management LLC lifted its holdings in Pacira BioSciences by 109.9% in the fourth quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after buying an additional 327,754 shares during the period. Numerai GP LLC purchased a new position in shares of Pacira BioSciences in the 4th quarter valued at approximately $296,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock valued at $491,000 after purchasing an additional 794 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Pacira BioSciences in the 4th quarter valued at approximately $8,558,000. Finally, Corton Capital Inc. lifted its stake in shares of Pacira BioSciences by 6.0% in the 4th quarter. Corton Capital Inc. now owns 21,575 shares of the company's stock valued at $406,000 after purchasing an additional 1,214 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.